الفهرس 
Title: Effect of some protein tyrosine-kinase inhibitors on experimental Schistosomiasis mansoni
AbstractOnly 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
Schistosomiasis mansoni is considered one of the most common fibrotic disease resulting from inflammation and deposition of fibrous tissue around parasitic eggs trapped in the liver, causing morbidity and mortality. It affects 210 million people worldwide and causing more than 280,000 deaths per year. Chemotherapy against schistosomiasis relies mainly on Praziquantel (PZQ); which is safe and effective anti-schistosomal drug, yet, the massive administration of this drug in endemic areas and its ineffectiveness towards the immature stages, have raised critical concerns against the development of parasitic drug resistance. Few drugs are directed to reverse the schistosomal hepatic fibrosis, especially at the chronic and advanced stages of the disease. Recently, Protein tyrosine kinase inhibitors are identified as potent anti-schistosomal and anti-fibrotic drugs against schistosomes, that may suppress and reverse S. mansoni induced liver fibrosis. The present study was designed to assess the anti-schistosomal activity of the protein tyrosine kinase inhibitors (Imatinab and Genistein) in comparison to praziquantel, in an in vivo study, in both acute and chronic S. mansoni infection using different parameters including; parasitological, histopathological and immunohistochemical studies. from the obtained results, we found that; Imatinib and Genistein showed a significant reduction in TWB and tissue egg load with elevation in percentage of degenerated ova, in comparison to the control groups, in both acute and chronic stages of infection